What Do You Do With Inconclusive
Percepta GSC classifies the risk of primary lung cancer to guide patient management when bronchoscopy is inconclusive.
The Percepta GSC measures gene expression alterations in bronchial epithelial cells collected from two brushings of the main stem airway of current or former smokers.
Be one of the first to offer the next-generation Percepta classifier to your patients.
Sign Up for Percepta GSC
Want to Learn More About Percepta GSC?
Veracyte's Medical Director, Dr. Sangeeta Bhorade, discusses the features, performance and development of Percepta GSC in a recorded clinical webinar. Select from any available event and register to watch.
Include Percepta GSC in Your Practice
Fast and simple to collect and order—
Percepta integrates seamlessly into your practice.
How confident are you in
your ILD/IPF diagnosis?
Envisia genomic classifier enables more confident IPF diagnosis by detecting a genomic pattern of UIP through transbronchial biopsy.
Up to 60% of patient cases with histopathologic UIP findings are missed by High Resolution CT (HRCT) alone.2,3 Envisia classifier is designed as a complement to HRCT and clinical factors for a more confident IPF diagnosis.
Be one of the first to offer this test.
sign up for the early access program
Newly published data in Lancet Respiratory Medicine demonstrated the Envisia classifier results informed ILD clinical diagnoses by identifying UIP with 88% specificity and 70% sensitivity.2
Read the Validation Study